1Goss PE, Ingle JN, Ales-Martlnez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women[J]. N En- gl J Med,2011,364(25) :2381-91.
2Early Breast Cancer Trialists' Collaborative Group(EBCTCG),Da- vies C,Godwin J, et al. Relevance of breast cancer hormone re ceptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta analysis of randomised trials[J]. Lancet, 2011,378(9793) :771 -84.
3Ellis MJ, Suman V J, Hoog J, et al. Randomized phase Ⅱ neoad- j uvant comparison between letrozole,anastrozole, and exeraes- tane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer~ clinical and biomarker outcomes and predictive value of the baseline PAMS0-based intrinsic subtype-- ACOSOG Z1031 [ J ]. J Clin Oncol, 2011,29 ( 17 ) 2342-9.
4Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-Positive breast cancer[J]. N Engl J Med, 2011,365 (14) :1273-83.
5Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable hu- man epidermal growth factor receptor 2-positive breast cancer:joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oneol,2011,29(25) :3366-73.
6Palmieria C,Jones A. The 2011 EBCTCG polychemotherapy o- verview[J]. Lancet,2012,379(9814) : 390-2.
7Gnant M. Long-term follow-up in ABCSG-12 : Signifieantly im- proved overall survival with adjuvant zoledronic acid in prem- enopausal patients with endocrine-receptor-positive early breast cancer[C]. SABCS. America: CTRC, Baylor, AACR, 2011 : Abstract S1-2.
8de Boer R. Long-term survival outcomes among postmenopaus- al women with hormone receptor-positive early breast cancer receiving adjuvant letrozole(drug information on letrozole) and zoledronic acid: 5-year follow-up of ZO-FAST[C]. SABCS. A- merica : CTRC, Baylor., AACR, 2011 : Abstract S1-3.
9Paterson AHG. NSABP protocol B-34.. a clinical trial compa- ring adjuvant clodronate vs. placebo in early stage breast canc- er patients receiving systemic chemotherapy and/or tamoxifen (drug information on tamoxifen) or no therapy--final analysis [C]. SABCS. America~ CTRC, Baylor, AACR, 2011 : Abstract S2-3.
10Mobus V. GAIN study: a phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node- positive primary breast cancer--lst interim efficacy analysis [C]. SABCS. America: CTRC, Baylor, AACR, 2011 ; Abstract S2-4.
8Rd B H,Lebrun F,Rugo H S,et al.Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3,randomized,controlled,BOLERO-2 trial.[J].Cancer,2013,119(10):1908.
9Jordan V C,Lewis J S,Osipo C,et al.The apoptotic action of estrogen following exhaustive antihormonal therapy:a new clinical treatment strategy[J].Breast,2005,14(6):624.
10Zhang Y,Simondsen K,Kolesar J M.Exemestane for primary prevention of breast cancer in postmenopausal women[J].Am J Health Syst Pharm,2012,69(16):1384.
